Lisata Therapeutics (NASDAQ:LSTA) Shares Down 5.1% – Should You Sell?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s stock price fell 5.1% during mid-day trading on Monday. The company traded as low as $1.50 and last traded at $1.50. Approximately 38,180 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 306,459 shares. The stock had previously closed at $1.58.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lisata Therapeutics currently has an average rating of “Reduce”.

Lisata Therapeutics Stock Down 5.1%

The company’s fifty day moving average is $1.47 and its two-hundred day moving average is $2.98. The stock has a market cap of $13.52 million, a price-to-earnings ratio of -0.91 and a beta of 0.94.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.32) EPS for the quarter. Sell-side analysts predict that Lisata Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

Several institutional investors have recently modified their holdings of LSTA. Bank of America Corp DE acquired a new position in shares of Lisata Therapeutics during the second quarter worth $35,000. SOL Capital Management CO acquired a new stake in Lisata Therapeutics in the first quarter valued at $61,000. BlackRock Inc. purchased a new stake in Lisata Therapeutics during the 2nd quarter worth about $187,000. Rangeley Capital LLC purchased a new stake in Lisata Therapeutics during the 1st quarter worth about $376,000. Finally, Deltec Asset Management LLC acquired a new position in shares of Lisata Therapeutics during the 1st quarter worth about $451,000. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies for the treatment of cancer. The company’s research is centered on improving the delivery of anticancer agents into solid tumors and addressing the biological barriers that can limit the effectiveness of conventional cancer treatments.

Lisata’s lead investigational product is certepetide, formerly known as LSTA-1. Certepetide is a tumor-penetrating peptide designed to selectively bind to neuropilin-1, a receptor associated with tumor vasculature and the tumor microenvironment.